Advertisement

Topics

Bristol─Myers receives European approval for Opdivo plus low dose Yervoy to treat patients with intermediate─ and advanced RCC

14:54 EST 15 Jan 2019 | PharmaBiz

Bristol─Myers Squibb Company announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (low─dose) for the first─line treatment

Original Article: Bristol─Myers receives European approval for Opdivo plus low dose Yervoy to treat patients with intermediate─ and advanced RCC

NEXT ARTICLE

More From BioPortfolio on "Bristol─Myers receives European approval for Opdivo plus low dose Yervoy to treat patients with intermediate─ and advanced RCC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...